ストックスクリーナーアプリを入手
9.74
0.71%
-0.07
プレマーケット:
9.85
0.11
+1.13%
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
What is HC Wainwright's Forecast for BCRX Q3 Earnings? - MarketBeat
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st
Discipline and Rules-Based Execution in BCRX Response - news.stocktradersdaily.com
Biocryst Pharmaceuticals Stock Price Forecast. Should You Buy BCRX? - StockInvest.us
RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares - Stock Titan
Research Analysts Issue Forecasts for BCRX Q4 Earnings - MarketBeat
Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - MarketBeat
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance
A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - MarketBeat
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options - Yahoo Finance
A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst? - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a 111.57% Potential Upside - DirectorsTalk Interviews
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
Weekly Recap: Q2 revenue jump, raised guidance and Astria R&D charge, shift - TradingView
BioCryst Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Strong-Buy at Wall Street Zen - MarketBeat
BCRX SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus
BioCryst Pharmaceuticals, Inc. (BCRX) Options Chain - Yahoo! Finance Canada
State Street Corporation (BCRX) discloses 15.2M BioCryst shares in 13G filing - Stock Titan
How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals (BCRX) Investors - Sahm
BCRX Maintained by RBC Capital -- Price Target Lowered to $13.00 - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price - MarketBeat
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
BCRX Maintained by Wedbush -- Price Target Lowered to $20.00 - GuruFocus
BioCryst WARN filing reveals 47 jobs affected by Birmingham research center closure - WBMA
Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price - MarketBeat
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) 2026-08-06 - Seeking Alpha
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Pacer Advisors Inc. Makes New $14.88 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Dimensional Fund Advisors LP Has $25.61 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Q2 2026 BioCryst Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call High - GuruFocus
BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside - TradingView
Astria deal drives large H1 loss at BioCryst Pharmaceuticals (Nasdaq: BCRX) - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating - Yahoo Finance
Earnings call transcript: BioCryst beats Q2 2026 estimates and lifts outlook - Investing.com
BioCryst Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
BioCryst Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2026 - marketscreener.com
BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised - marketscreener.com
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is BioCryst Pharmaceuticals Inc (BCRX) Undervalued After Q2 Earn - GuruFocus
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
North Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham area - AL.com
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 FY2026 earnings call transcript - Yahoo Finance
Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15 - marketscreener.com
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M - marketscreener.com
BioCryst: Q2 Earnings Snapshot - Yahoo Finance
BioCryst Starts Shipping ORLADEYO Oral Pellets to Pediatric Patients - Stock Titan
BioCryst earnings on deck: Can Orladeyo sustain momentum? - Investing.com
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: Significant Upside Potential with 138% Growth Prospects - DirectorsTalk Interviews
Renaissance Technologies LLC Sells 1,351,831 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Perceptive Advisors LLC Acquires 4,271,504 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
First Trust Advisors LP Buys 425,939 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Janus Henderson Group PLC Grows Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:BCRX - TradingView
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update - MarketBeat
BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
0.79%
5.15%
大文字化:
|
ボリューム (24 時間):